+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension



Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension



Pediatric Cardiology 34(4): 1006-1012



Acute pulmonary vasodilator testing (AVT) is essential to determining the initial therapy for children with pulmonary arterial hypertension (PAH). This study aimed to report the initial experience with inhaled treprostinil used for AVT in children with PAH and to evaluate the hemodynamic change after inhaled treprostinil compared with inhaled nitric oxide. This prospective cohort study was designed for 13 children who underwent AVT with inhaled treprostinil or oxygen plus inhaled nitric oxide (iNO) during catheterization. Inhaled treprostinil was delivered during cardiac catheterization by adapting the Optineb ultrasonic nebulizer via either a flow-inflating bag or the manual mode of the anesthesia system. The median age of the patients was 10 years (range 4-17 years). The etiologies of PAH included idiopathic PAH and associated PAH. All the patients tolerated inhaled treprostinil without marked clinical worsening and received six or nine breaths (36 or 54 μg) of treprostinil. The median of the total treprostinil doses was 1.53 μg/kg (range 0.71-2.89 μg/kg). Inhaled treprostinil was administrated via an endotracheal tube (n = 8), anesthesia mask (n = 3), or laryngeal mask airway (n = 2). Inhaled nitric oxide (iNO) and inhaled treprostinil significantly decreased the mean pulmonary artery pressure and the pulmonary vascular resistance index compared with baseline. Three adverse events were reported after inhaled treprostinil, including cough and mild to moderate hypotension with higher doses. All adverse events resolved without any intervention. This study report is the first to describe the use of inhaled treprostinil for AVT in children with PAH. In this small pediatric cohort, inhaled treprostinil was effectively delivered and well tolerated and may be useful for AVT.

(PDF emailed within 0-6 h: $19.90)

Accession: 051363171

Download citation: RISBibTeXText

PMID: 23184020

DOI: 10.1007/s00246-012-0597-9


Related references

Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. Journal of Heart and Lung Transplantation 30(12): 1327-1333, 2012

Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. Pulmonary Circulation 3(1): 116-120, 2013

Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension. Pulmonary Circulation 4(3): 456-461, 2015

Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. American Journal of Cardiology 110(11): 1704-1709, 2013

Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series. Journal of Pharmacy Practice: 897190017703507-897190017703507, 2017

Inhaled iloprost during acute pulmonary vasodilator testing for preoperative assessment of surgical operability of congenital heart disease with severe pulmonary hypertension. Zhonghua Wai Ke Za Zhi 48(10): 727-730, 2011

Adenosine for pulmonary vasodilator testing in children with idiopathic pulmonary arterial hypertension. Zhonghua Er Ke Za Zhi 49(12): 886-889, 2013

Acute pulmonary vasodilator testing is a critical step in the management of patients with pulmonary arterial hypertension. Zhonghua Jie He He Hu Xi Za Zhi 31(5): 378-380, 2008

Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. Pulmonary Pharmacology & Therapeutics, 2018

Inhaled hexadecyl-treprostinil provides pulmonary vasodilator activity at significantly lower plasma concentrations than infused treprostinil. Pulmonary Pharmacology & Therapeutics 49: 104-111, 2018

Rapid transition from inhaled iloprost to inhaled treprostinil in patients with pulmonary arterial hypertension. Cardiovascular Therapeutics 31(1): 38-44, 2013

Inhaled treprostinil and pulmonary arterial hypertension. Vascular Health and Risk Management 6: 1115-1124, 2011

Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension. Clinica Chimica Acta; International Journal of Clinical Chemistry 446(): 272-276, 2016

Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. Journal of the American Society of Echocardiography 25(3): 274-279, 2012

Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Expert Review of Respiratory Medicine 6(3): 255-265, 2012